Targeting the PI3K/Akt/mTOR pathway in ocular neovascularization

Area of Science:

• Ophthalmology
• Molecular Biology
• Medical Research

Background:

• Ocular neovascularization, a hallmark of wet age-related macular degeneration and diabetic retinopathy, causes vision loss due to leakage and scarring.
• Anti-vascular endothelial growth factor (VEGF) therapies are current treatments but have drawbacks including side effects and high costs.
• The phosphatidylinositol-3-kinase (PI3K) pathway is implicated in cellular processes like growth, survival, and angiogenesis.

Purpose of the Study:

• To review the therapeutic potential of targeting the PI3K pathway for ocular neovascularization.
• To explore the PI3K/Akt/mTOR pathway as an alternative to anti-VEGF treatments.
• To discuss the advantages of targeting the PI3K pathway in angiogenic eye diseases.

Main Methods:

• Literature review of studies on ocular neovascularization.
• Analysis of the role of the PI3K/Akt/mTOR pathway in angiogenesis.
• Evaluation of PI3K pathway inhibitors as potential treatments.

Main Results:

• The PI3K pathway plays a crucial role in angiogenesis.
• Targeting the PI3K pathway presents a viable alternative to anti-VEGF agents.
• PI3K inhibition may offer a new therapeutic strategy for neovascular eye diseases.

Conclusions:

• The PI3K pathway is a significant therapeutic target for ocular neovascularization.
• Targeting PI3K may provide a more effective and safer treatment option.
• Further research into PI3K inhibitors is warranted for treating blinding eye conditions.